Hemolytic-uremic syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
Shyam Patel (talk | contribs) No edit summary |
Shyam Patel (talk | contribs) (→HUS) |
||
| Line 156: | Line 156: | ||
| pmid = 19160220 | | pmid = 19160220 | ||
}}</ref> | }}</ref> | ||
** | ** Maintain adequate [[hydration]] and<nowiki/> [[electrolyte]]<nowiki/>s during infection by ample fluid ther<nowiki/>apy effects on short and long-term disease outcomes.<ref>{{Cite journal | ||
| author = [[Gianluigi Ardissino]], [[Francesca Tel]], [[Ilaria Possenti]], [[Sara Testa]], [[Dario Consonni]], [[Fabio Paglialonga]], [[Stefania Salardi]], [[Nicolo Borsa-Ghiringhelli]], [[Patrizia Salice]], [[Silvana Tedeschi]], [[Pierangela Castorina]], [[Rosaria Maria Colombo]], [[Milena Arghittu]], [[Laura Daprai]], [[Alice Monzani]], [[Rosangela Tozzoli]], [[Maurizio Brigotti]] & [[Erminio Torresani]] | | author = [[Gianluigi Ardissino]], [[Francesca Tel]], [[Ilaria Possenti]], [[Sara Testa]], [[Dario Consonni]], [[Fabio Paglialonga]], [[Stefania Salardi]], [[Nicolo Borsa-Ghiringhelli]], [[Patrizia Salice]], [[Silvana Tedeschi]], [[Pierangela Castorina]], [[Rosaria Maria Colombo]], [[Milena Arghittu]], [[Laura Daprai]], [[Alice Monzani]], [[Rosangela Tozzoli]], [[Maurizio Brigotti]] & [[Erminio Torresani]] | ||
| title = Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome | | title = Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome | ||
| Line 180: | Line 167: | ||
| pmid = 26644486 | | pmid = 26644486 | ||
}}</ref> | }}</ref> | ||
** Indications for [[dialysis]] in children with<nowiki/> [[Hemolytic-uremic syndrome|HUS]] are similar to those in children with other forms of | ** Indications for [[dialysis]] in children with<nowiki/> [[Hemolytic-uremic syndrome|HUS]] are similar to those in children with other forms of [[acute kidney injury]] ([[Acute kidney injury|AKI]]).<ref>{{Cite journal | ||
| author = [[Jennifer G. Jetton]], [[Louis J. Boohaker]], [[Sidharth K. Sethi]], [[Sanjay Wazir]], [[Smriti Rohatgi]], [[Danielle E. Soranno]], [[Aftab S. Chishti]], [[Robert Woroniecki]], [[Cherry Mammen]], [[Jonathan R. Swanson]], [[Shanty Sridhar]], [[Craig S. Wong]], [[Juan C. Kupferman]], [[Russell L. Griffin]] & [[David J. Askenazi]] | | author = [[Jennifer G. Jetton]], [[Louis J. Boohaker]], [[Sidharth K. Sethi]], [[Sanjay Wazir]], [[Smriti Rohatgi]], [[Danielle E. Soranno]], [[Aftab S. Chishti]], [[Robert Woroniecki]], [[Cherry Mammen]], [[Jonathan R. Swanson]], [[Shanty Sridhar]], [[Craig S. Wong]], [[Juan C. Kupferman]], [[Russell L. Griffin]] & [[David J. Askenazi]] | ||
| title = Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study | | title = Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study | ||
| Line 193: | Line 180: | ||
}}</ref> | }}</ref> | ||
* '''Anemia''' | * '''Anemia''' | ||
** | ** Transfuse packed [[Red blood cell|red blood cells]]<nowiki/>[[Red blood cell|ls]] ([[RBC]]):<ref>{{Cite journal | ||
| author = [[J. R. Brandt]], [[L. S. Fouser]], [[S. L. Watkins]], [[I. Zelikovic]], [[P. I. Tarr]], [[V. Nazar-Stewart]] & [[E. D. Avner]] | | author = [[J. R. Brandt]], [[L. S. Fouser]], [[S. L. Watkins]], [[I. Zelikovic]], [[P. I. Tarr]], [[V. Nazar-Stewart]] & [[E. D. Avner]] | ||
| title = Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers | | title = Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers | ||
| Line 207: | Line 194: | ||
*** Hematocrit < 18 | *** Hematocrit < 18 | ||
** Transfusion should be done slowly and patients should be obsereved close<nowiki/>ly. | ** Transfusion should be done slowly and patients should be obsereved close<nowiki/>ly. | ||
** Monitor | ** Monitor the plasma [[potassium]] to prevent [[hyperkalemia]]. | ||
** | ** Maintain a goal Hgb level after transfiution of between 8-9 g/dL<nowiki/>. | ||
** Do no<nowiki/>t try to normalize the hemoglobin as it may lead to heart failur<nowiki/>e, [[pulmonary edema]] and<nowiki/> [[hypertension]] due to <nowiki/>volume overload.<ref>{{Cite journal | ** Do no<nowiki/>t try to normalize the hemoglobin as it may lead to heart failur<nowiki/>e, [[pulmonary edema]] and<nowiki/> [[hypertension]] due to <nowiki/>volume overload.<ref>{{Cite journal | ||
| author = [[B. S. Kaplan]], [[P. D. Thomson]] & [[J. P. de Chadarevian]] | | author = [[B. S. Kaplan]], [[P. D. Thomson]] & [[J. P. de Chadarevian]] | ||
| Line 220: | Line 207: | ||
| pmid = 792781 | | pmid = 792781 | ||
}}</ref> | }}</ref> | ||
** Patients who | ** Patients who undergo hemodialysis, [[transfusions]] sh<nowiki/>ould be given during [[dialysis]] to minimize the risks of [[hypervolemia]]<nowiki/> and [[hyperkalemia]].<ref>{{Cite journal | ||
| author = [[Hoon Young Choi]] & [[Sung Kyu Ha]] | | author = [[Hoon Young Choi]] & [[Sung Kyu Ha]] | ||
| title = Potassium balances in maintenance hemodialysis | | title = Potassium balances in maintenance hemodialysis | ||
| Line 233: | Line 220: | ||
}}</ref> | }}</ref> | ||
* '''Thrombocytopenia''' | * '''Thrombocytopenia''' | ||
** Patients w<nowiki/>ith [[Hemolytic-uremic syndrome|HUS]] who are | ** Patients w<nowiki/>ith [[Hemolytic-uremic syndrome|HUS]] who are noted to have significant clinical [[bleeding]] or who require an [[Invasive (medical)|invasive]] [[procedure]] should receive [[platelet]] [[transfusions]]<ref>{{Cite journal | ||
| author = [[Phillip I. Tarr]], [[Carrie A. Gordon]] & [[Wayne L. Chandler]] | | author = [[Phillip I. Tarr]], [[Carrie A. Gordon]] & [[Wayne L. Chandler]] | ||
| title = Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome | | title = Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome | ||
| Line 262: | Line 249: | ||
* '''[[Neurologic dysfunction]]''' | * '''[[Neurologic dysfunction]]''' | ||
** Patients with serious [[neurologic]] [[dysfunction]] | ** Patients with serious [[neurologic]] [[dysfunction]] should undergo brain [[imaging]] performed to assess [[CNS]] involvement.<ref>{{Cite journal | ||
| author = [[Andreas Greinacher]], [[Sigrun Friesecke]], [[Peter Abel]], [[Alexander Dressel]], [[Sylvia Stracke]], [[Michael Fiene]], [[Friedlinde Ernst]], [[Kathleen Selleng]], [[Karin Weissenborn]], [[Bernhard M. W. Schmidt]], [[Mario Schiffer]], [[Stephan B. Felix]], [[Markus M. Lerch]], [[Jan T. Kielstein]] & [[Julia Mayerle]] | | author = [[Andreas Greinacher]], [[Sigrun Friesecke]], [[Peter Abel]], [[Alexander Dressel]], [[Sylvia Stracke]], [[Michael Fiene]], [[Friedlinde Ernst]], [[Kathleen Selleng]], [[Karin Weissenborn]], [[Bernhard M. W. Schmidt]], [[Mario Schiffer]], [[Stephan B. Felix]], [[Markus M. Lerch]], [[Jan T. Kielstein]] & [[Julia Mayerle]] | ||
| title = Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial | | title = Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial | ||
| Line 273: | Line 260: | ||
| doi = 10.1016/S0140-6736(11)61253-1 | | doi = 10.1016/S0140-6736(11)61253-1 | ||
| pmid = 21890192 | | pmid = 21890192 | ||
}}</ref>[[Seizure|Seizures]] are treated with [[Antiepileptic drugs|antiepileptic agents]] | }}</ref>[[Seizure|Seizures]] are treated with [[Antiepileptic drugs|antiepileptic agents]].<ref>{{Cite journal | ||
| author = [[Mini Michael]], [[Elizabeth J. Elliott]], [[Greta F. Ridley]], [[Elisabeth M. Hodson]] & [[Jonathan C. Craig]] | | author = [[Mini Michael]], [[Elizabeth J. Elliott]], [[Greta F. Ridley]], [[Elisabeth M. Hodson]] & [[Jonathan C. Craig]] | ||
| title = Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura | | title = Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura | ||
Latest revision as of 02:35, 21 December 2018
|
Hemolytic-uremic syndrome Microchapters |
|
Differentiating Hemolytic-uremic syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hemolytic-uremic syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Hemolytic-uremic syndrome medical therapy |
|
Risk calculators and risk factors for Hemolytic-uremic syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
The mainstay of therapy for hemolytic uremic syndrome (HUS) is supportive therapy. Antibiotic therapy is not recommended among patients with HUS. Hydration and intravenous (IV) isotonic saline replacment decrease the risk of hemolytic-uremic syndrome (HUS). Patients with HUS who have significant clinical bleeding or who require an invasive procedure should receive platelet transfusions.
Medical Therapy
- The mainstay of therapy for HUS is supportive therapy and almost all cases of HUS are self-limited.[1] However any patient suspected of HUS should be referred to a kidney center or nephrology unit or be managed in an intensive care unit.
- Antibiotic therapy is not recommended among patients with E. coli O157:H7 infection. This increases the risk of HUS. However there are some antibiotics that decrease the risk of HUS such as quinolones.[2][3][4][5]
- Heparin, anti-platelet agents, immunoadsorption, thrombomodulin (rhTM).[6]
- Fosfomycin should be started within 48-72 hours of the patient's presentation of HUS.[7]
- Empiric antibiotic therapy such as cephalosporins for invasive pneumococcal disease should be used following culture results.
- Recombinant human soluble thrombomodulin (rTM)[8] is a novel medicine that use to treat children with HUS.[9][10][11]
- Eculizumab is used to treat atypical HUS.[12]
HUS
- Acute kidney injury
- First discontinue medicines that have renal toxicity.[13]
- Fluid replacement is the mainstay of treatment.[14]
- Maintain adequate hydration and electrolytes during infection by ample fluid therapy effects on short and long-term disease outcomes.[15]
- Indications for dialysis in children with HUS are similar to those in children with other forms of acute kidney injury (AKI).[16]
- Anemia
- Transfuse packed red blood cellsls (RBC):[17]
- Hemoglobin <6 g/dL
- Hematocrit < 18
- Transfusion should be done slowly and patients should be obsereved closely.
- Monitor the plasma potassium to prevent hyperkalemia.
- Maintain a goal Hgb level after transfiution of between 8-9 g/dL.
- Do not try to normalize the hemoglobin as it may lead to heart failure, pulmonary edema and hypertension due to volume overload.[18]
- Patients who undergo hemodialysis, transfusions should be given during dialysis to minimize the risks of hypervolemia and hyperkalemia.[19]
- Transfuse packed red blood cellsls (RBC):[17]
- Thrombocytopenia
- Hypertension
- At the first indication of hypertension fluids should be restricted. Dialysis is more effective than diuretics.
- Calcium channel blockers should be used as the initial choice of antihypertensive agents and after this phase antihypertensive therapy should be changed to ACE inhibitors in patients who appear to have long-term renal sequelae.[21]
- Neurologic dysfunction
- Patients with serious neurologic dysfunction should undergo brain imaging performed to assess CNS involvement.[22]Seizures are treated with antiepileptic agents.[23]
References
- ↑ Silviu Grisaru (2014). "Management of hemolytic-uremic syndrome in children". International journal of nephrology and renovascular disease. 7: 231–239. doi:10.2147/IJNRD.S41837. PMID 24966691.
- ↑ C. S. Wong, S. Jelacic, R. L. Habeeb, S. L. Watkins & P. I. Tarr (2000). "The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections". The New England journal of medicine. 342 (26): 1930–1936. doi:10.1056/NEJM200006293422601. PMID 10874060. Unknown parameter
|month=ignored (help) - ↑ Nasia Safdar, Adnan Said, Ronald E. Gangnon & Dennis G. Maki (2002). "Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis". JAMA. 288 (8): 996–1001. PMID 12190370. Unknown parameter
|month=ignored (help) - ↑ G. Z. Panos, G. I. Betsi & M. E. Falagas (2006). "Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection?". Alimentary pharmacology & therapeutics. 24 (5): 731–742. doi:10.1111/j.1365-2036.2006.03036.x. PMID 16918877. Unknown parameter
|month=ignored (help) - ↑ Paul N. Goldwater & Karl A. Bettelheim (2012). "Treatment of enterohemorrhagic Escherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS)". BMC medicine. 10: 12. doi:10.1186/1741-7015-10-12. PMID 22300510. Unknown parameter
|month=ignored (help) - ↑ . doi:10.1097/INF.0b013e31823096a8. Check
|doi=value (help). Missing or empty|title=(help) - ↑ K. Ikeda, O. Ida, K. Kimoto, T. Takatorige, N. Nakanishi & K. Tatara (1999). "Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection". Clinical nephrology. 52 (6): 357–362. PMID 10604643. Unknown parameter
|month=ignored (help) - ↑ Yukihiko Kawasaki, Kazuhide Suyama, Atsushi Ono, Tomoko Oikawa, Shinichiro Ohara, Yuichi Suzuki, Nobuko Sakai & Mitsuaki Hosoya (2013). "Efficacy of recombinant human soluble thrombomodulin for childhood hemolytic uremic syndrome". Pediatrics international : official journal of the Japan Pediatric Society. 55 (5): e139–e142. doi:10.1111/ped.12165. PMID 24134770. Unknown parameter
|month=ignored (help) - ↑ Takashi Honda, Shohei Ogata, Eri Mineo, Yukako Nagamori, Shinya Nakamura, Yuki Bando & Masahiro Ishii (2013). "A novel strategy for hemolytic uremic syndrome: successful treatment with thrombomodulin alpha". Pediatrics. 131 (3): e928–e933. doi:10.1542/peds.2012-1466. PMID 23382444. Unknown parameter
|month=ignored (help) - ↑ Lindsay S. Keir, Stephen D. Marks & Jon Jin Kim (2012). "Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies". Drug design, development and therapy. 6: 195–208. doi:10.2147/DDDT.S25757. PMID 22888220.
- ↑ Marina Noris & Giuseppe Remuzzi (2005). "Hemolytic uremic syndrome". Journal of the American Society of Nephrology : JASN. 16 (4): 1035–1050. doi:10.1681/ASN.2004100861. PMID 15728781. Unknown parameter
|month=ignored (help) - ↑ Rawaa Ebrahem, Salam Kadhem & Quoc Truong (2017). "Treatment of Atypical Hemolytic-Uremic Syndrome in the Era of Eculizumab". Cureus. 9 (3): e1111. doi:10.7759/cureus.1111. PMID 28439485. Unknown parameter
|month=ignored (help) - ↑ Mini Michael, Elizabeth J. Elliott, Jonathan C. Craig, Greta Ridley & Elisabeth M. Hodson (2009). "Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials". American journal of kidney diseases : the official journal of the National Kidney Foundation. 53 (2): 259–272. doi:10.1053/j.ajkd.2008.07.038. PMID 18950913. Unknown parameter
|month=ignored (help) - ↑ Mini Michael, Elizabeth J. Elliott, Greta F. Ridley, Elisabeth M. Hodson & Jonathan C. Craig (2009). "Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura". The Cochrane database of systematic reviews (1): CD003595. doi:10.1002/14651858.CD003595.pub2. PMID 19160220. Unknown parameter
|month=ignored (help) - ↑ Gianluigi Ardissino, Francesca Tel, Ilaria Possenti, Sara Testa, Dario Consonni, Fabio Paglialonga, Stefania Salardi, Nicolo Borsa-Ghiringhelli, Patrizia Salice, Silvana Tedeschi, Pierangela Castorina, Rosaria Maria Colombo, Milena Arghittu, Laura Daprai, Alice Monzani, Rosangela Tozzoli, Maurizio Brigotti & Erminio Torresani (2016). "Early Volume Expansion and Outcomes of Hemolytic Uremic Syndrome". Pediatrics. 137 (1). doi:10.1542/peds.2015-2153. PMID 26644486. Unknown parameter
|month=ignored (help) - ↑ Jennifer G. Jetton, Louis J. Boohaker, Sidharth K. Sethi, Sanjay Wazir, Smriti Rohatgi, Danielle E. Soranno, Aftab S. Chishti, Robert Woroniecki, Cherry Mammen, Jonathan R. Swanson, Shanty Sridhar, Craig S. Wong, Juan C. Kupferman, Russell L. Griffin & David J. Askenazi (2017). "Incidence and outcomes of neonatal acute kidney injury (AWAKEN): a multicentre, multinational, observational cohort study". The Lancet. Child & adolescent health. 1 (3): 184–194. doi:10.1016/S2352-4642(17)30069-X. PMID 29732396. Unknown parameter
|month=ignored (help) - ↑ J. R. Brandt, L. S. Fouser, S. L. Watkins, I. Zelikovic, P. I. Tarr, V. Nazar-Stewart & E. D. Avner (1994). "Escherichia coli O 157:H7-associated hemolytic-uremic syndrome after ingestion of contaminated hamburgers". The Journal of pediatrics. 125 (4): 519–526. PMID 7931869. Unknown parameter
|month=ignored (help) - ↑ B. S. Kaplan, P. D. Thomson & J. P. de Chadarevian (1976). "The hemolytic uremic syndrome". Pediatric clinics of North America. 23 (4): 761–777. PMID 792781. Unknown parameter
|month=ignored (help) - ↑ Hoon Young Choi & Sung Kyu Ha (2013). "Potassium balances in maintenance hemodialysis". Electrolyte & blood pressure : E & BP. 11 (1): 9–16. doi:10.5049/EBP.2013.11.1.9. PMID 23946760. Unknown parameter
|month=ignored (help) - ↑ Phillip I. Tarr, Carrie A. Gordon & Wayne L. Chandler (2005). "Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome". Lancet (London, England). 365 (9464): 1073–1086. doi:10.1016/S0140-6736(05)71144-2. PMID 15781103. Unknown parameter
|month=ignored (help) - ↑ Phillip I. Tarr, Carrie A. Gordon & Wayne L. Chandler (2005). "Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome". Lancet (London, England). 365 (9464): 1073–1086. doi:10.1016/S0140-6736(05)71144-2. PMID 15781103. Unknown parameter
|month=ignored (help) - ↑ Andreas Greinacher, Sigrun Friesecke, Peter Abel, Alexander Dressel, Sylvia Stracke, Michael Fiene, Friedlinde Ernst, Kathleen Selleng, Karin Weissenborn, Bernhard M. W. Schmidt, Mario Schiffer, Stephan B. Felix, Markus M. Lerch, Jan T. Kielstein & Julia Mayerle (2011). "Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial". Lancet (London, England). 378 (9797): 1166–1173. doi:10.1016/S0140-6736(11)61253-1. PMID 21890192. Unknown parameter
|month=ignored (help) - ↑ Mini Michael, Elizabeth J. Elliott, Greta F. Ridley, Elisabeth M. Hodson & Jonathan C. Craig (2009). "Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura". The Cochrane database of systematic reviews (1): CD003595. doi:10.1002/14651858.CD003595.pub2. PMID 19160220. Unknown parameter
|month=ignored (help)